Bolt Biotherapeutics Q2 Loss Narrows to $7.72M, Cash Runway Into Q1 2027
BOLT is trading near its 52-week low of $3.75 (6.1% above the low) on light trading volume (0.2× avg).
Summary
Bolt Biotherapeutics reported Q2 results with a net loss of $7.72 million, narrowing from prior year on lower R&D and G&A expenses after restructuring. Collaboration revenue collapsed to just $5,000. The company ended the quarter with $18.1 million in cash, which management expects to fund operations into Q1 2027 — consistent with the going-concern warning in the 10-Q filed today. The BDC-4182 Phase 1/2 trial in gastric cancers advanced to Cohort 4, with initial clinical data expected in Q3 2026. The cash position remains precarious; without new funding, survival beyond early 2027 is uncertain.
At the time of this announcement, BOLT was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $3.75 to $7.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.